PAVmed Cost Of Revenue vs Total Revenue Analysis
PAVMZ Stock | USD 0.01 0.0001 0.66% |
PAVmed Series financial indicator trend analysis is much more than just breaking down PAVmed Series Z prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PAVmed Series Z is a good investment. Please check the relationship between PAVmed Series Cost Of Revenue and its Total Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Cost Of Revenue vs Total Revenue
Cost Of Revenue vs Total Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PAVmed Series Z Cost Of Revenue account and Total Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between PAVmed Series' Cost Of Revenue and Total Revenue is -0.43. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Total Revenue in the same time period over historical financial statements of PAVmed Series Z, assuming nothing else is changed. The correlation between historical values of PAVmed Series' Cost Of Revenue and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of PAVmed Series Z are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Cost Of Revenue i.e., PAVmed Series' Cost Of Revenue and Total Revenue go up and down completely randomly.
Correlation Coefficient | -0.43 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Cost Of Revenue
Cost of Revenue is found on PAVmed Series Z income statement and represents the costs associated with goods and services PAVmed Series provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Revenue
Total revenue comprises all receipts PAVmed Series Z generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Most indicators from PAVmed Series' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PAVmed Series Z current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. At this time, PAVmed Series' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 29.4 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 11.99 in 2024.
PAVmed Series fundamental ratios Correlations
Click cells to compare fundamentals
PAVmed Series Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PAVmed Series fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 7.2M | 19.8M | 87.0M | 54.0M | 33.1M | 23.6M | |
Other Current Liab | 1.4M | (15.0M) | 4.3M | 3.7M | 6.6M | 7.0M | |
Total Current Liabilities | 11.9M | 20.0M | 7.6M | 41.2M | 54.2M | 56.9M | |
Total Stockholder Equity | (3.8M) | 1.9M | 61.7M | (9.7M) | (53.8M) | (51.1M) | |
Net Debt | 1.9M | (2.3M) | (77.3M) | (3.1M) | 29.1M | 30.5M | |
Retained Earnings | (53.7M) | (88.3M) | (138.9M) | (228.2M) | (294.4M) | (279.7M) | |
Cash | 6.2M | 17.3M | 77.3M | 39.7M | 19.6M | 18.9M | |
Cash And Short Term Investments | 6.2M | 17.3M | 77.3M | 39.7M | 19.6M | 18.9M | |
Liabilities And Stockholders Equity | 7.2M | 19.8M | 87.0M | 54.0M | 33.1M | 23.6M | |
Capital Surpluse | 14.0M | 32.6M | 47.6M | 87.6M | 100.7M | 105.7M | |
Other Current Assets | 328.3B | 1.7M | 5.2M | 3.9M | 4.3M | 4.0M | |
Other Stockholder Equity | 47.6M | 87.6M | 198.1M | 215.9M | 237.6M | 249.5M | |
Total Liab | 11.9M | 20.3M | 7.6M | 43.0M | 57.1M | 60.0M | |
Total Current Assets | 6.5M | 18.9M | 82.6M | 43.9M | 24.5M | 20.8M | |
Common Stock | 40.5K | 64K | 86K | 95K | 9K | 8.6K | |
Accounts Payable | 2.4M | 3.0M | 3.3M | 2.7M | 1.8M | 2.1M | |
Non Current Assets Total | 692.9K | 837K | 4.3M | 10.1M | 8.6M | 9.1M | |
Common Stock Shares Outstanding | 2.0M | 3.2M | 5.2M | 5.9M | 7.2M | 7.6M | |
Non Current Liabilities Total | 10.5M | 300K | 4.3B | 1.8M | 3.0M | 2.8M | |
Short Long Term Debt Total | 7.9M | 8.1M | 15.0M | 36.6M | 48.7M | 51.2M | |
Net Invested Capital | 2.0M | 14.3M | 59.2M | 21.3M | (12.6M) | (12.0M) | |
Net Working Capital | (5.3M) | (1.0M) | 75.1M | 2.7M | (29.7M) | (28.2M) | |
Capital Stock | 2.3M | 2.6M | 2.5M | 2.8M | 3.0M | 2.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for PAVmed Stock Analysis
When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.